CTRI/2024/02/062710招募中3 期
Addition of low-dose pembrolizumab to capecitabine for residual triple negative breast cancer post neoadjuvant chemotherapy: An investigator-initiated multicentric open-labelled phase III randomized controlled clinical trial - SCRIPT Trial
试验速览
- 阶段
- 3 期
- 状态
- 招募中
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Patients who sign informed consent.
- •2. Patients who have residual disease after NACT and Surgery.
排除标准
- •1. Patients who have pathological complete response.
- •2. Patients who have contraindication of any Auto Immune Disorder.
- •3. Patients who have only DCIS present in their residual disease.
研究者
相似试验
尚未招募
不适用
Phase II study of pembrolizumab + capecitabine/oxaliplatin (CapeOx) in metastatic GC as first-line treatmentNeoplasmsKCT0004775Samsung Medical Center68
招募中
2 期
PEMBROCABOSARC : Combination of pembrolizumab and cabozantinib in patients with advanced sarcomas2023-509496-16-00Institut Bergonie99
进行中（未招募）
2 期
Pembrolizumab plus chemotherapy for diffuse large B-cell lymphoma that has come back or does not respond to treatmentCancerISRCTN86607306niversity Hospital Southampton NHS Foundation Trust65
进行中（未招募）
2 期
Phase II study of chemotheraphy and ICI for elderly patients with advanced non-squamous cell lung canceradvanced non-squamous cell lung cancerJPRN-jRCTs051190095Kanai Kuninobu22
进行中（未招募）
1 期
A phase II study of Pembrolizumab plus Carboplatin in BRCA-related metastatic breast cancerEUCTR2016-001314-25-ITAZIENDA OSPEDALIERO-UNIVERSITARIA DI MODENA53